Clinical Trial Update: Dose-Ranging Safety and Efficacy Study of Topical Creams Containing API 31510 for the Treatment of in Situ Cutaneous Squamous Cell Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 dose-ranging safety and efficacy study of topical creams containing API 31510 for in situ cutaneous squamous cell carcinoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Squamous Cell Carcinoma

Drugs mentioned

• API 31510 topical cream (API 31510)

Snippet

Sponsor: BPGbio | Conditions: Squamous Cell Carcinoma | Phase 2 | Status: WITHDRAWN